Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 6/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22980521 | 1.00 | PIK3CA (0.37) | PIK3CANLRP3GRM5RAB9AEGLN1 | |
| SCHEMBL24467941 | 0.92 | PIK3CA (0.41) | PIK3CANLRP3GRM5RAB9A | |
| SCHEMBL29434787 | 0.92 | PIK3CA (0.41) | PIK3CANLRP3GRM5RAB9A | |
| Trifluoroacetic Acid SCHEMBL22980338 | 0.81 | SLC40A1 (0.39) | PIK3CAEGLN1EGLN3NR3C2KDR | |
| SCHEMBL22982184 | 0.79 | GRM4 (0.41) | PIK3CANLRP3RAB9A | |
| SCHEMBL22980522 | 0.76 | GRM5 (0.33) | PIK3CAGRM5 | |
| Trifluoroacetic Acid SCHEMBL22980528 | 0.75 | ACLY (0.34) | PIK3CAEGLN1EGLN3 | |
| SCHEMBL29434888 | 0.71 | SLC40A1 (0.44) | PIK3CAGRM5KDRKAT6A | |
| SCHEMBL22980265 | 0.71 | SLC40A1 (0.44) | PIK3CAGRM5KDRKAT6A | |
| Trifluoroacetic Acid SCHEMBL28718812 | 0.69 | HSD11B1 (0.39) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | claimed |
| EP-4013495-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | claimed |
| US-12065399-B2 | Arylsulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4013495-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | ARSA, SULT1E1, STS | PIK3CA 1815/4885NLRP3 2573/4885GRM5 4194/4885 |
| US-12065399-B2 | Arylsulfonamide derivatives | ARSA, SULT1E1, STS | PIK3CA 1815/4885NLRP3 2573/4885GRM5 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.